BioWorld

March 13, 2002

Myriad, Abbott Team In Deal To Diagnose, Treat Depression

Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today) Read More

Ricerca Licenses Cancer Gene; CRO Embraces New Paradigm’

Classic Mutant Mouse With Multi- Neuronal Disorders Shines Light On Potential Human Manipulation

Alexion, CuraGen Seek Cancer Targets For Drug Development

Phenomix’s Forward Genetics’ Gets $32M Funding Commitment

Other News To Note

Senomyx Raises $36.8M Privately To Fund Taste, Smell Programs

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...